Critical

Cytokine release syndrome (CAR-T / immunotherapy)

Systemic inflammatory response · Shock / Sepsis
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Immune-cell therapies (CAR-T, bispecific antibodies) can trigger a systemic cytokine storm with fever, hypotension and hypoxia, sometimes with neurotoxicity (ICANS). Supportive care plus tocilizumab and steroids by grade are the mainstays.

Assessment

Investigations

  • Identify recent CAR-T/immunotherapy
  • Septic screen (CRS mimics sepsis)
  • Grade severity (fever, vasopressor/oxygen need)
  • Assess for neurotoxicity (ICANS)

Management

  • Resuscitate and cover for sepsis until excluded
  • Tocilizumab for significant CRS
  • Corticosteroids for higher grades or neurotoxicity
  • Organ support (vasopressors, oxygen) as needed
  • Haematology/oncology and ICU involvement

Drugs & doses

Tocilizumab
Corticosteroids
Vasopressors / fluids

Disposition

ICU; haematology.

Fever and shock days after CAR-T is cytokine release syndrome - treat sepsis in parallel, and reach for tocilizumab.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.